DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

03 Dec 2019

HIV on Trial

Meet our research team, hear from some of our research participants and learn more about the DolPHIN story so far.

Video

28 Nov 2019

They become strong when they see me doing this

Jackie Kyeyune, a peer mother living with HIV, discusses how she uses her lived experience to support and inspire the DolPHIN 2 trial participants.

Video

28 Nov 2019

Trial Management at the Ugandan site

Dr Kenneth Kintu, trial manager at the IDI site, discusses the challenges and rewards of the study, and his hopes for the future

Video

28 Nov 2019

All Hands on Deck

Study Paediatrician Jesca Nakibuka describes the importance of a multidisciplary approach in the DolPHIN 2 clinical study

Video

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

RT @CatrionaWaitt: Really important call to action: ensure equitable access to HIV treatments, protection from AEs and ensure full res… https://t.co/qhzgenCwXs

3 weeks 4 days ago

Have a look at this article about DolPHIN2 by @LivUni #MTCT #pregnancy #DTG https://t.co/od6O0CiPej

1 month 2 hours ago

RT @CatrionaWaitt: It's National Breastfeeding Celebration Week, but if mothers require medical treatment, gaps in data can lead to re… https://t.co/puLfuORNyF

2 months 1 day ago

RT @covidDDIs: The first three months of our website have seen fantastic engagement. Please keep reaching out and letting us know… https://t.co/UhlZykEucA

2 months 1 day ago

RT @UCTIDM: Affiliate Member Prof Landon Myer is part of the initial team which devised the app CareConekta which aims to inves… https://t.co/HmsY07LYHm

2 months 1 week ago

RT @covidDDIs: The COVID-19 DDI website now has a fully interactive drug interaction checker, like our sister sites.… https://t.co/Gk7cxSfYyL

2 months 3 weeks ago

RT @justinchiong: The wonderful Dr Lamorde is a long time collaborator in various research projects, including the DolPHIN2 study… https://t.co/TevKk20ngf

2 months 3 weeks ago

Happy #InternationalNursesDay2020 to all our DolPHIN2 nurses. Watch one of our nurses describe a typical day https://t.co/LieI3JZwg2

2 months 3 weeks ago

RT @EpiBiostats_UCT: Congratulations to the many members of the Division contributing to this study including @myer_landon @t_hoko… https://t.co/n8RjtPt5d5

2 months 3 weeks ago

RT @TheLancetHIV: In the May issue: dolutegravir versus efavirenz in women starting #HIV therapy in late #pregnancy @UoLDolphin2… https://t.co/eyY8peaa5W

2 months 3 weeks ago

DolPHIN2 data support revision to @WHO guidelines recommending transition to #DTG in first-line ART for all adults,… https://t.co/PGc7yLTpNk

3 months 19 hours ago

DolPHIN2 paper out today. #DTG superior to #EFV in reducing viral load by delivery when ART initiated in third trim… https://t.co/YAJuyb31RM

3 months 19 hours ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

HIV on Trial

They become strong when they see me doing this

Trial Management at the Ugandan site

All Hands on Deck

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us